Alessandro Chiesi appointed Chair of the Chiesi Group Maria Paola Chiesi becomes the Vice Chair
07 Luglio 2023
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
23 Giugno 2023
Chiesi Global Rare Diseases Announces FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
10 Maggio 2023
Chiesi Global Rare Diseases Announces European Commission (EC) Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
05 Maggio 2023
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
12 Aprile 2023
2022 for Chiesi: The Group’s international growth continues
05 Aprile 2023
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
01 Marzo 2023
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
07 Marzo 2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
25 Febbraio 2023
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting